Pharmacology ACS Pharmacology & Translational Science
PTP4A3 Flagged as AML Prognostic Marker; JMS-053 Inhibitor Synergises with Cytarabine In Vitro
- High PTP4A3 expression tracked with poor outcomes, genomic instability, oncogenic signalling and poorly differentiated myeloid populations in AML datasets.
- The inhibitor JMS-053 reduced leukaemic cell viability and colony formation across several AML models, with apoptotic signalling and lower ERK1/2 phosphorylation.
- It was synergistic with cytarabine.
Target validation here rests on expression correlations and a tool compound, and JMS-053 is a known promiscuous-looking phosphatase inhibitor, so on-target proof needs PTP4A3 knockout or rescue. The cytarabine synergy is the translational hook, but I'd want normal haematopoietic cells and an in vivo model to see whether any therapeutic window exists.
Paper: ACS Pharmacology & Translational Science ↗ Protein Tyrosine Phosphatase 4A3 (PTP4A3) as a Prognostic Biomarker and Pharmacological Target in Acute Myeloid Leukemia